Prophylactic lamivudine to improve the outcome of HBsAg-positive lymphoma patients during chemotherapy: a systematic review and meta-analysis.
Li, Hong; Zhang, Hong-Min; Chen, Li-Fen; Chen, Ya-Qin; Chen, Ling; Ren, Hong; Hu, Huai-Dong.
Clin Res Hepatol Gastroenterol
; 39(1): 80-92, 2015 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-25199680
Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance.
Fatal reactivation of occult hepatitis B virus infection after rituximab and chemotherapy in lymphoma: necessity of antiviral prophylaxis.
Reactivation of hepatitis B virus in patients with undetectable HBsAg undergoing chemotherapy for malignant lymphoma or multiple myeloma.
[Analysis of the prophylactic effect of nucleosides against reactivation of HBV in HBsAg-positive patients with non-hepatic tumors after chemotherapy].
Antibody therapies for lymphoma in children.
Management of hepatitis B reactivation in lymphoma patients on rituximab with past hepatitis B exposure: An observational study.
Surveillance scanning in lymphoma.
[Exosomes in the hematopoietic system].
Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy.
Singling out the out-of-tune in lymphoma.